Edition:
India

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

3.75USD
1:30am IST
Change (% chg)

$0.25 (+7.14%)
Prev Close
$3.50
Open
$3.60
Day's High
$3.85
Day's Low
$3.60
Volume
407,161
Avg. Vol
127,447
52-wk High
$5.80
52-wk Low
$2.20

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Says Working With Sandoz To Prepare Symjepi Launch
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS PROVIDES BUSINESS UPDATE.ADAMIS PHARMACEUTICALS - WORKING CLOSELY WITH SANDOZ TO PREPARE A SUCCESSFUL LAUNCH FOR SYMJEPI.ADAMIS PHARMACEUTICALS - FDA PROVIDED PDUFA DATE OF SEPT 27, 2018 FOR LOW DOSE SYMJEPI PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS - LOW DOSE SYMJEPI PRODUCT CANDIDATE IS STILL UNDER REVIEW WITH U.S. FDA.  Full Article

Adamis Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Adamis Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS CORP FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.  Full Article

Adamis Pharmaceuticals Says Unless Earlier Terminated, Deal With Sandoz Will Expire 10 Yrs From Launch Of Product
Monday, 2 Jul 2018 

July 2 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS - DEAL WITH SANDOZ FOR SYMJEPI PROVIDES SANDOZ WILL PAY TO CO 50% OF NET PROFIT FROM NET SALES OF PRODUCT.ADAMIS PHARMACEUTICALS - UNLESS EARLIER TERMINATED, DEAL WITH SANDOZ WILL EXPIRE 10 YRS FROM LAUNCH OF PRODUCT, WITH ANNUAL RENEWAL TERMS THEREAFTER.  Full Article

Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE.  Full Article

Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI.ADAMIS PHARMACEUTICALS CORP - SUBMISSION OF A PRIOR APPROVAL SUPPLEMENT TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDIATRIC VERSION (0.15MG) OF SYMJEPI.  Full Article